Covid: DCGI panel clears Corbevax for 12-18 age group

Tribune News Service

Updated At : 11:37 AM Feb 15, 2022 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

New Delhi, February 14

The subject experts committee of the Drug Controller General of India (DCGI) has recommended granting emergency use authorisation to Biological E’s Covid vaccine for 12 to 18-year-olds.

The DCGI had on December 28 last year approved Corbevax, which is India’s first indigenous RBD protein sub-unit vaccine, for restricted use in emergency situation in adults. It has not been included in the country’s vaccination drive yet. The government is yet to take a decision on vaccinating those aged below 15 years.

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles